Sernova management cites cost-saving cuts to R&D, finance costs as Q3 ended July 31 net loss narrows to CAD 2.53 million

Reuters2026/09/11 14:59

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Management commentary covered the three and nine months ended July 31, 2026, with net loss of CAD 2.53 million in Q3.
Loss narrowed from CAD 4.07 million, driven by lower R&D spending from reduced trial activity and iPSC program costs.
R&D expense fell to CAD 432,624 from CAD 1.74 million; finance costs declined to CAD 260,183 from CAD 541,676.
Higher foreign-exchange loss weighed on results, reflecting revaluation of mainly U.S.-dollar accounts payable as the Canadian dollar weakened.
Nine-month net loss was CAD 8.09 million versus CAD 13.55 million, reflecting cost cuts partly offset by higher finance costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sernova Biotherapeutics Inc. published the original content used to generate this news brief on September 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Sernova management cites cost-saving cuts to R&D, finance costs as Q3 ended July 31 net loss narrows to CAD 2.53 million

You may also like

Crypto prices